Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction
| Autor: | Angela C Rieger, Bryon A Tompkins, Makoto Natsumeda, Victoria Florea, Monisha N Banerjee, Jose Rodriguez, Marcos Rosado, Valeria Porras, Krystalenia Valasaki, Lauro M Takeuchi, Kevin Collon, Sohil Desai, Michael A Bellio, Aisha Khan, Nilesh D Kashikar, Ana Marie Landin, Darrell V Hardin, Daniel A Rodriguez, Wayne Balkan, Joshua M Hare, Ivonne Hernandez Schulman |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Stem Cells Translational Medicine. 11:59-72 |
| ISSN: | 2157-6580 2157-6564 |
| Popis: | Background Left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) are primary manifestations of the cardiorenal syndrome in patients with chronic kidney disease (CKD). Therapies that improve morbidity and mortality in HFpEF are lacking. Cell-based therapies promote cardiac repair in ischemic and non-ischemic cardiomyopathies. We hypothesized that cell-based therapy ameliorates CKD-induced HFpEF. Methods and Results Yorkshire pigs (n = 26) underwent 5/6 embolization-mediated nephrectomy. CKD was confirmed by increased creatinine and decreased glomerular filtration rate (GFR). Mean arterial pressure (MAP) was not different between groups from baseline to 4 weeks. HFpEF was evident at 4 weeks by increased LV mass, relative wall thickening, end-diastolic pressure, and end-diastolic pressure-volume relationship, with no change in ejection fraction (EF). Four weeks post-embolization, allogeneic (allo) bone marrow-derived mesenchymal stem cells (MSC; 1 × 107 cells), allo-kidney-derived stem cells (KSC; 1 × 107 cells), allo-cell combination therapy (ACCT; MSC + KSC; 1:1 ratio; total = 1 × 107 cells), or placebo (Plasma-Lyte) was delivered via intra-renal artery. Eight weeks post-treatment, there was a significant increase in MAP in the placebo group (21.89 ± 6.05 mmHg) compared to the ACCT group. GFR significantly improved in the ACCT group. EF, relative wall thickness, and LV mass did not differ between groups at 12 weeks. EDPVR improved in the ACCT group, indicating decreased ventricular stiffness. Conclusions Intra-renal artery allogeneic cell therapy was safe in a CKD swine model manifesting the characteristics of HFpEF. The beneficial effect on renal function and ventricular compliance in the ACCT group supports further research of cell therapy for cardiorenal syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|